The Role of Encorafenib in BRAF-Positive Advanced Cancers

Encorafenib, supplied under the brand name Braftovi. As a targeted therapy, it is used for patients whose cancer has a BRAF V600 mutation. This mutation causes uncontrolled cell growth and leads to aggressive forms of cancer. This therapeutic drug works by blocking abnormal BRAF signals. It helps slow down or stop the progression of cancer. Encorafenib is prescribed along with other medicinal products depending on the type of cancer being treated.

Encorafenib (Braftovi) is a prescription drug, approved for treating three major conditions:
BRAF+ metastatic colorectal cancer
BRAF+ metastatic non-small cell lung cancer
BRAF+ metastatic melanoma that is difficult to remove by surgery

Braftovi for BRAF+ Metastatic Melanoma:

Many patients diagnosed with melanoma have a BRAF V600 mutation. When the melanoma becomes metastatic and difficult to manage by surgery, a targeted approach is used. Encorafenib, often used along with binimetinib. It helps slow tumor growth and increase response rates. This combination treatment allows patients to receive treatment even if the disease has progressed to other important organs.

Braftovi for BRAF+ Metastatic Colorectal Cancer:

In colorectal cancer, BRAF mutations are less common but more aggressive. For BRAF+ metastatic colorectal cancer, Encorafenib is used along with cetuximab. This regimen targets the mutation and the cancer growth pathway together, helping patients who have progressed after initial therapies. This combination has become an important therapeutic option in later-line treatment settings.

Braftovi for BRAF+ Metastatic Non-Small Cell Lung Cancer:

Some cases of BRAF+ metastatic non-small cell lung cancer (NSCLC) also carry the BRAF V600E mutation. When Encorafenib is used together with binimetinib, it offers a targeted approach for these patients. This treatment slows down disease progression and supports improved outcomes where traditional chemotherapy alone may not be as effective.

Patient Monitoring and Safety:

Like all cancer drugs, Encorafenib needs regular monitoring. Routine blood tests, skin checks, and regular assessments for liver or heart function are required. Dosing instructions must be carefully followed. Report any new signs and symptoms immediately.

References:

1. Braftovi (Encorafenib) – U.S. FDA Prescribing Information
2. National Cancer Institute – BRAF Gene Mutations Explained
3. NCCN Clinical Practice Guidelines in Oncology – Melanoma
4. NCCN Guidelines – Colon/Rectal Cancer (BRAF-mutated CRC treatment)
5. NCCN Guidelines – Non-Small Cell Lung Cancer (Targeted Therapy Section)
6. European Medicines Agency – Braftovi Product Information
7. ASCO – Targeted Therapy for BRAF-Mutated Melanoma
8. ASCO – Targeted Therapy for Colorectal Cancer
9. ASCO – Lung Cancer Targeted Therapy Overview